• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Scott J. Rodig, MD, PhD


  • Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson MM, Nademanee AP, Niland JC, Rodig SJ, Rodriguez MA, Zelenetz AD, LaCasce AS.Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.Cancer. 2014 Jul 1(13):1993-9.
  • Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, Scullen TA, Burke JN, Rodig SJ, Hideshima T, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Weller EA, Richardson PG, Raje NS.Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.British Journal of Haematology. 2014 Apr 25.
  • Pozdnyakova O, Wu K, Patki A, Rodig SJ, Thiele J, Hasserjian RP.High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms.Mod Pathol. 2014 Apr 25.
  • Hao Y, Chapuy B, Monti S, Sun HH, Rodig SJ, Shipp MA.Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo.Clin Cancer Res. 2014 Apr 22.
  • Xiao R, Cerny J, Devitt K, Dresser K, Nath R, Ramanathan M, Rodig SJ, Chen BJ, Woda BA, Yu H.MYC Protein Expression Is Detected in Plasma Cell Myeloma but Not in Monoclonal Gammopathy of Undetermined Significance (MGUS).Am J Surg Pathol. 2014 Apr 3.
  • Bailey ST, Miron PL, Choi YJ, Kochupurakkal B, Maulik G, Rodig SJ, Tian R, Foley KM, Bowman T, Miron A, Brown M, Iglehart JD, Biswas DK.NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth.Mol Cancer Res. 2014 Mar;12(3):408-20.
  • Hsi ED, Said J, Macon WR, Rodig SJ, Ondrejka SL, Gascoyne RD, Morgan EA, Dorfman DM, Maurer MJ, Dogan A.Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas: A North American PTCL Study Group Project.Am J Surg Pathol. 2014 Mar 10.
  • Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, Weinstock DM.A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.Blood. 2014 Feb 27;123(9):1293-6.
  • Katz SG, Labelle JL, Meng H, Valeriano RP, Fisher JK, Sun H, Rodig SJ, Kleinstein SH, Walensky LD.Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells.Blood. 2014 Feb 6;123(6):884-93.
  • Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, Hu R, Harrell JC, McNamara G, Schwede M, Culhane AC, Kindelberger D, Rodig S, Richardson A, Schnitt SJ, Tamimi RM, Ince TA.Taxonomy of breast cancer based on normal cell phenotype predicts outcome.J Clin Invest. 2014 Feb 3;124(2):859-70.
  • Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA, Bradner JE.Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.Cancer Cell. 2013 Dec 9;24(6):777-90.
  • Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK.Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.Cancer Discovery. 2013 Dec(12):1355-63.
  • Odejide OO, Cronin AM, DeAngelo DJ, Bernazzoli ZA, Jacobson JO, Rodig SJ, LaCasce AS, Mazeika TJ, Earles KD, Abel GA.Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist.Cancer. 2013 Oct 1;119(19):3472-8.
  • Sholl LM, Sun H, Butaney M, Zhang C, Lee C, Jänne PA, Rodig SJ.ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.Am J Surg Pathol. 2013 Sep;37(9):1441-9.
  • Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS.Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma.British Journal of Haematology. 2013 Oct;163(1):123-6.
  • Wesemann DR, Portuguese AJ, Meyers RM, Gallagher MP, Cluff-Jones K, Magee JM, Panchakshari RA, Rodig SJ, Kepler TB, Alt FW.Microbial colonization influences early B-lineage development in the gut lamina propria.Nature. 2013 Sep 5;501(7465):112-5.
  • Heinrichs S, Conover LF, Bueso-Ramos CE, Kilpivaara O, Stevenson K, Neuberg D, Loh ML, Wu WS, Rodig SJ, Garcia-Manero G, Kantarjian HM, Look AT.MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy.Elife. 2013;2:e00825.
  • Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, Dorfman D, Pinkus G, Weigert O, Hornick JL, Chirieac LR, Hirsch M, Oh DJ, South AP, Leigh IM, Pourreyron C, Cassidy AJ, Deangelo DJ, Weinstock DM, Krop IE, Dillon D, Brock JE, Lazar AJ, Peto M, Cho RJ, Stoeck A, Haines BB, Sathayanrayanan S, Rodig S, Aster JC.Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.PLoS ONE. 2013;8(6):e67306.
  • Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ.PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.Clin Cancer Res. 2013 Jul 1;19(13):3462-73.
  • Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, Doench JG, Bogusz AM, Habermann TM, Dogan A, Witzig TE, Kutok JL, Rodig SJ, Golub T, Shipp MA.SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.Cancer Cell. 2013 Jun 10;23(6):826-38.
  • Bowman-Colin C, Xia B, Bunting S, Klijn C, Drost R, Bouwman P, Fineman L, Chen X, Culhane AC, Cai H, Rodig SJ, Bronson RT, Jonkers J, Nussenzweig A, Kanellopoulou C, Livingston DM.Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.Proc Natl Acad Sci U S A. 2013 May 8.
  • Kluk MJ, Ryan KP, Wang B, Zhang G, Rodig SJ, Sanchez T.Sphingosine-1-phosphate receptor 1 in classical Hodgkin lymphoma: assessment of expression and role in cell migration.Lab Invest. 2013 Apr;93(4):462-71.
  • Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A.KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.British Journal of Haematology. 2013 Apr;161(1):117-27.
  • Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J.Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.Blood. 2013 Feb 21;121(8):1296-303.
  • Gostissa M, Bianco JM, Malkin DJ, Kutok JL, Rodig SJ, Morse HC, Bassing CH, Alt FW.Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas.Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2934-9.
  • Jia D, Hasso SM, Chan J, Filingeri D, D'Amore PA, Rice L, Pampo C, Siemann DW, Zurakowski D, Rodig SJ, Moses MA.Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo.Blood. 2013 Jan 24;121(4):707-15.
  • Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, Mansour MR, Barcelo C, McCauley D, Kauffman M, Shacham S, Christie AL, Kung AL, Rodig SJ, Chook YM, Look AT.Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.Leukemia. 2013 Jan;27(1):66-74.
  • Rodig SJ, Cheng J, Wardzala J, DoRosario A, Scanlon JJ, Laga AC, Martinez-Fernandez A, Barletta JA, Bellizzi AM, Sadasivam S, Holloway DT, Cooper DJ, Kupper TS, Wang LC, DeCaprio JA.Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus.J Clin Invest. 2012 Dec 3;122(12):4645-53.
  • Bogusz AM, Baxter RH, Currie T, Sinha P, Sohani AR, Kutok JL, Rodig SJ.Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma.Clin Cancer Res. 2012 Nov 15;18(22):6122-35.
  • Shindoh N, Yoda A, Yoda Y, Sullivan TJ, Weigert O, Lane AA, Kopp N, Bird L, Rodig SJ, Fox EA, Weinstock DM.Next-generation cDNA screening for oncogene and resistance phenotypes.PLoS ONE. 2012;7(11):e49201.
  • Barnes J, Jacobsen E, Feng Y, Freedman A, Hochberg E, Lacasce A, Armand P, Joyce R, Sohani A, Rodig S, Neuberg D, Fisher D, Abramson J.Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.Haematologica. 2012 Nov 9.
  • Laderach DJ, Gentilini L, Giribaldi L, Cardenas Delgado V, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G, Mazza O, Shipp MA, Vazquez ES, Chauchereau A, Kutok JL, Rodig SJ, Elola MT, Compagno D, Rabinovich GA.A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.Cancer Res. 2012 Oct 29.
  • Nehra D, Le HD, Fallon EM, Carlson SJ, Woods D, White YA, Pan AH, Guo L, Rodig SJ, Tilly JL, Rueda BR, Puder M.Prolonging the female reproductive lifespan and improving egg quality with dietary omega-3 fatty acids.Aging Cell. 2012 Sep 15.
  • Calado DP, Sasaki Y, Godinho SA, Pellerin A, Köchert K, Sleckman BP, de Alborán IM, Janz M, Rodig S, Rajewsky K.The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers.Nat Immunol. 2012 Nov;13(11):1092-100.
  • Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DM.BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.Blood. 2012 Oct 4;120(14):2843-52.
  • Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI.Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.Clin Cancer Res. 2012 Sep 15;18(18):4973-85.
  • Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT, Inguilizian H, Mermel C, Currie T, Dogan A, Kutok JL, Beroukhim R, Neuberg D, Habermann TM, Getz G, Kung AL, Golub TR, Shipp MA.Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma.Cancer Cell. 2012 Sep 11;22(3):359-72.
  • Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT.Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.Nat Med. 2012 Jul;18(7):1118-22.
  • Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, Rodig SJ, Sohani AR, Harris NL, Laramie JM, Skifter DA, Lincoln SE, Hunter ZR.MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.N Engl J Med. 2012 Aug 30;367(9):826-33.
  • Sander S, Calado DP, Srinivasan L, Köchert K, Zhang B, Rosolowski M, Rodig SJ, Holzmann K, Stilgenbauer S, Siebert R, Bullinger L, Rajewsky K.Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.Cancer Cell. 2012 Aug 14;22(2):167-79.
  • Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, Wilson D, Das S, Shapiro GI.Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.Invest New Drugs. 2012 Jun 2.
  • Ciccarelli BT, Patterson CJ, Hunter ZR, Hanzis C, Ioakimidis L, Manning R, Yang G, Xu L, Zhou Y, Sun J, Liu X, Tseng H, Cao Y, Sheehy P, Rodig SJ, Treon SP.Hepcidin Is Produced by Lymphoplasmacytic Cells and Is Associated With Anemia in Waldenström's Macroglobulinemia.Clin Lymphoma Myeloma Leuk. 2011 Feb 1;11(1):160-3.
  • Sung CK, Dahl J, Yim H, Rodig S, Benjamin TL.Transcriptional and post-translational regulation of the quiescence factor and putative tumor suppressor p150Sal2.FASEB J. 2011 Apr;25(4):1275-83.
  • Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig SJ, Vallet S, Pozzi S, Patel K, Unitt CL, Squires MS, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje NS.Anti-myeloma activity of a multi targeted kinase inhibitor, AT9283, via potent Aurora Kinase and STAT3 inhibition either alone or in combination with lenalidomide.Clin Cancer Res. 2011 Mar 23.
  • Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG.Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.Lancet Oncol. 2011 Mar;12(3):263-72.
  • Green MR, Monti S, Dalla-Favera R, Pasqualucci L, Walsh NC, Schmidt-Supprian M, Kutok JL, Rodig SJ, Neuberg DS, Rajewsky K, Golub TR, Alt FW, Shipp MA, Manis JP.Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program.Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2873-8.
  • Ouyang J, Juszczynski P, Rodig SJ, Green MR, O'Donnell E, Currie T, Armant M, Takeyama K, Monti S, Rabinovich GA, Ritz J, Kutok JL, Shipp MA.Viral induction and targeted inhibition of galectin-1 in EBV+ post-transplant lymphoproliferative disorders.Blood. 2011 Feb 7.
  • Koh KP, Yabuuchi A, Rao S, Huang Y, Cunniff K, Nardone J, Laiho A, Tahiliani M, Sommer CA, Mostoslavsky G, Lahesmaa R, Orkin SH, Rodig SJ, Daley GQ, Rao A.Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells.Cell Stem Cell. 2011 Feb 4;8(2):200-13.
  • Runnels JM, Carlson AL, Pitsillides C, Thompson B, Wu J, Spencer JA, Kohler JM, Azab A, Moreau AS, Rodig SJ, Kung AL, Anderson KC, Ghobrial IM, Lin CP.Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy.J Biomed Opt.;16(1):011006.
  • Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, Reynolds R, O'Connor KC, Hafler DA.Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis.Brain. 2011 Feb;134(Pt 2):534-41.
  • Fiorina P, Jurewicz M, Vergani A, Petrelli A, Carvello M, D'Addio F, Godwin JG, Law K, Wu E, Tian Z, Thoma G, Kovarik J, La Rosa S, Capella C, Rodig S, Zerwes HG, Sayegh MH, Abdi R.Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1.J Immunol. 2011 Jan 1;186(1):121-31.
  • Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, Shapiro GI, Rodig SJ, Eck MJ, Jänne PA.The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.Cancer Res. 2010 Dec 15;70(24):10038-43.
  • Calado DP, Zhang B, Srinivasan L, Sasaki Y, Seagal J, Unitt C, Rodig S, Kutok J, Tarakhovsky A, Schmidt-Supprian M, Rajewsky K.Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma.Cancer Cell. 2010 Dec 14;18(6):580-9.
  • Rodig SJ, Shapiro GI.Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90.
  • Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, Xu C, Wang Y, Aldelmant GO, Capelletti M, Lee HJ, Rodig SJ, Borgman CL, Park SI, Kim HR, Padera RF, Marto J, Gray N, Kung AL, Shapiro GI, Janne PA, Wong KK.Inhibition of ALK, PI3K/MEK and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene.Cancer Res. 2010 Dec 1;70(23):9827-36.
  • Rodig SJ, Kutok JL, Paterson JC, Nitta H, Zhang W, Chapuy B, Tumwine LK, Montes-Moreno S, Agostinelli C, Johnson NA, Ben-Neriah S, Farinha P, Shipp MA, Piris MA, Grogan TM, Pileri SA, Gascoyne RD, Marafioti T.The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker to identify c-MYC translocated lymphomas.Haematologica. 2010 Dec;95(12):2056-62.
  • Boenisch O, D'Addio F, Watanabe T, Elyaman W, Magee CN, Yeung MY, Padera RF, Rodig SJ, Murayama T, Tanaka K, Yuan X, Ueno T, Jurisch A, Mfarrej B, Akiba H, Yagita H, Najafian N.TIM-3: A Novel Regulatory Molecule of Alloimmune Activation.J Immunol. 2010 Nov 15;185(10):5806-19.
  • Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA.Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.Blood. 2010 Oct 28;116(17):3268-77.
  • Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD, Shapiro GI.Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.N Engl J Med. 2010 Oct 28;363(18):1727-33.
  • Vergani A, D'Addio F, Jurewicz M, Petrelli A, Watanabe T, Liu K, Law K, Schuetz C, Carvello M, Orsenigo E, Deng S, Rodig SJ, Ansari JM, Staudacher C, Abdi R, Williams J, Markmann J, Atkinson M, Sayegh MH, Fiorina P.A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice.Diabetes. 2010 Sep;59(9):2253-64.
  • Sasaki T, Rodig SJ, Chirieac LR, Jänne PA.The biology and treatment of EML4-ALK non-small cell lung cancer.Eur J Cancer. 2010 Jul;46(10):1773-80. Review.
  • O'Brien KB, Alberich-Jordà M, Yadav N, Kocher O, Diruscio A, Ebralidze A, Levantini E, Sng NJ, Bhasin M, Caron T, Kim D, Steidl U, Huang G, Halmos B, Rodig SJ, Bedford MT, Tenen DG, Kobayashi S.CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cells.Development. 2010 Jul;137(13):2147-56.
  • Ruzinova MB, Caron T, Rodig SJ.Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation.Am J Surg Pathol. 2010 Jun;34(6):882-91.
  • Spivey KA, Banyard J, Solis LM, Wistuba II, Barletta JA, Gandhi L, Feldman HA, Rodig SJ, Chirieac LR, Zetter BR.Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer.Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1362-72.
  • Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N.Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.Mol Cancer Ther. 2010 Apr;9(4):963-75.
  • Juszczynski P, Rodig SJ, Ouyang J, O'Donnell E, Takeyama K, Mlynarski W, Mycko K, Szczepanski T, Gaworczyk A, Krivtsov A, Faber J, Sinha AU, Rabinovich GA, Armstrong SA, Kutok JL, Shipp MA.MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.Clin Cancer Res. 2010 Apr 1;16(7):2122-30.
  • Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, Cohen DW, Johnson BE, Jänne PA, Iafrate AJ, Rodig SJ.A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.Clin Cancer Res. 2010 Mar 1;16(5):1561-71.
  • Bertrand KA, Spiegelman D, Aster JC, Altshul LM, Korrick SA, Rodig SJ, Zhang SM, Kurth T, Laden F.Plasma organochlorine levels and risk of non-Hodgkin lymphoma in a cohort of men.Epidemiology. 2010 Mar;21(2):172-80.
  • Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG.Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.Clin Cancer Res. 2010 Feb 1;16(3):1033-41.
  • Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM.Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):252-7.
  • Willis SN, Stadelmann C, Rodig SJ, Caron T, Gattenloehner S, Mallozzi SS, Roughan JE, Almendinger SE, Blewett MM, Brück W, Hafler DA, O'Connor KC.Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.Brain. 2009 Dec;132(Pt 12):3318-28.
  • Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ.Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK.J Clin Oncol. 2009 Sep 10;27(26):4247-53.
  • Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR.Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.Clin Cancer Res. 2009 Aug 15;15(16):5216-23.
  • Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN, Capella C, Rodig S, Adra CN, Atkinson M, Sayegh MH, Abdi R.Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes.J Immunol. 2009 Jul 15;183(2):993-1004.
  • Snyder EL,Sandstrom DJ,Law K,Fiore C,Sicinska E,Brito J,Bailey D,Fletcher JA,Loda M,Rodig SJ,Dal Cin P,Fletcher CD.c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme.J Pathol. 2009 Jul;218(3):292-300.
  • Riccio A,Li Y,Moon J,Kim KS,Smith KS,Rudolph U,Gapon S,Yao GL,Tsvetkov E,Rodig SJ,Van't Veer A,Meloni EG,Carlezon WA Jr,Bolshakov VY,Clapham DE.Essential role for TRPC5 in amygdala function and fear-related behavior.Cell. 2009 May 15;137(4):761-72.
  • Yang J,Bielenberg DR,Rodig SJ,Doiron R,Clifton MC,Kung AL,Strong RK,Zurakowski D,Moses MA.Lipocalin 2 promotes breast cancer progression.Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3913-8.
  • Cornejo MG,Kharas MG,Werneck MB,Le Bras S,Moore SA,Ball B,Beylot-Barry M,Rodig SJ,Aster JC,Lee BH,Cantor H,Merlio JP,Gilliland DG,Mercher T.Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.Blood. 2009 Mar 19;113(12):2746-54.
  • Babbe H,McMenamin J,Hobeika E,Wang J,Rodig SJ,Reth M,Leder P.Genomic instability resulting from Blm deficiency compromises development, maintenance, and function of the B cell lineage.J Immunol. 2009 Jan 1;182(1):347-60.
  • Rodig SJ,Ouyang J,Juszczynski P,Currie T,Law K,Neuberg DS,Rabinovich GA,Shipp MA,Kutok JL.AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.Clin Cancer Res. 2008 Jun 1;14(11):3338-44.
  • Rodig SJ, Vergilio JA, Shahsafaei A, Dorfman DM.Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation.Am J Surg Pathol. 2008 Jan;32(1):113-22.
  • Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD.Adaptive immunity maintains occult cancer in an equilibrium state.Nature. 2007 Dec 6;450(7171):903-7.
  • Rodig SJ, Payne EG, Degar BA, Rollins B, Feldman AL, Jaffe ES, Androkites A, Silverman LB, Longtine JA, Kutok JL, Fleming MD, Aster JC.Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1.Am J Hematol. 2008 Feb;83(2):116-21.
  • Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA, Shipp MA.The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma.Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13134-9.
  • Rodig SJ, Savage KJ, LaCasce AS, Weng AP, Harris NL, Shipp MA, Hsi ED, Gascoyne RD, Kutok JL.Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma.Am J Surg Pathol. 2007 Jan;31(1):106-12.
  • Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL.Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).Clin Cancer Res. 2006 Dec 1;12(23):7174-9.
  • Rodig SJ, Healey BM, Pinkus GS, Kuo FC, Cin PD, Kutok JL.Mantle cell lymphoma arising within primary nodal marginal zone lymphoma: a unique presentation of two uncommon B-cell lymphoproliferative disorders.Cancer Genet Cytogenet. 2006 Nov;171(1):44-51.
  • Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM.BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders.Hum Pathol. 2005 Oct;36(10):1113-9.
  • Rodig SJ, Shahsafaei A, Li B, Dorfman DM.The CD45 isoform B220 identifies select subsets of human B cells and B-cell lymphoproliferative disorders.Hum Pathol. 2005 Jan;36(1):51-7.
  • Rodig SJ, Savage KJ, Nguyen V, Pinkus GS, Shipp MA, Aster JC, Kutok JL.TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas.Am J Surg Pathol. 2005 Feb;29(2):196-203.
  • Rodig SJ, Jones D, Shahsafaei A, Dorfman DM.CCR6 is a functional chemokine receptor that serves to identify select B-cell non-Hodgkin's lymphomas.Hum Pathol. 2002 Dec;33(12):1227-33.
  • Rodig SJ, Dorfman DM.Splendore-Hoeppli phenomenon.Arch Pathol Lab Med. 2001 Nov;125(11):1515-6.
  • Hu J, Roy SK, Shapiro PS, Rodig SR, Reddy SP, Platanias LC, Schreiber RD, Kalvakolanu DV.ERK1 and ERK2 activate CCAAAT/enhancer-binding protein-beta-dependent gene transcription in response to interferon-gamma.J Biol Chem. 2001 Jan 5;276(1):287-97.
  • Satoskar AR, Rodig S, Telford SR, Satoskar AA, Ghosh SK, von Lichtenberg F, David JR.IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology.Eur J Immunol. 2000 Mar;30(3):834-9.
  • Rodig S, Kaplan D, Shankaran V, Old L, Schreiber RD.Signaling and signaling dysfunction through the interferon gamma receptor.Eur Cytokine Netw. 1998 Sep;9(3 Suppl):49-53.
  • Migone TS, Rodig S, Cacalano NA, Berg M, Schreiber RD, Leonard WJ.Functional cooperation of the interleukin-2 receptor beta chain and Jak1 in phosphatidylinositol 3-kinase recruitment and phosphorylation.Mol Cell Biol. 1998 Nov;18(11):6416-22.
  • Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KC, Yin L, Pennica D, Johnson EM, Schreiber RD.Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses.Cell. 1998 May 1;93(3):373-83.
  • Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD.Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway.Cell. 1996 Feb 9;84(3):431-42.